期刊文献+

Metabolite identification and the development of a simultaneous quantification method for wogonin and wogonin-7-O-glucuronide:application to a distribution study in mice liver 被引量:1

代谢产物鉴定及汉黄芩素与汉黄芩素-7-O-葡萄糖醛酸苷的同时测定:小鼠肝脏的分布研究(英文)
原文传递
导出
摘要 Wogonin possesses potent inhibitory activities against cancer cell growth in vitro and in vivo and has attractive safety profiles.A highly sensitive liquid chromatography coupled with tandem mass spectrometry method was developed for the identification of major metabolites in mice liver after intravenous administration of wogonin.Five metabolites were identified and biotransformation pathways were elucidated as well.Furthermore,a method was developed and validated for the simultaneous quantitatively determination of wogonin and wogonin-7-O-glucuronide in mice liver.After liquid-liquid extraction by ethyl acetate,the analytes were separated on a C_(18)column with a mobile phase of methanol-10 mM ammonium acetate water (80:20,v/v).The detection was operated with negative selected reaction monitoring mode using electrospray ionization technique. The linear response range was 0.2-40μg/g for both wogonin and wogonin-7-O-glucuronide in mice liver.The developed quantification method was suitable for distribution study after intravenous infusion of wogonin injection in animals. 汉黄芩素具有体内外抗肿瘤活性及良好的安全性。本文采用高效液相色谱串联质谱法研究了小鼠静脉注射汉黄芩素后肝脏中的代谢产物,鉴定了五个主要的代谢产物。建立了小鼠肝脏中汉黄芩素及其代谢产物汉黄芩素-7-O-葡萄糖醛酸苷的同时测定方法。肝匀浆经醋酸乙酯提取,在C_(18)色谱柱上,采用甲醇-10 mm醋酸铵(80:20,v/v)为流动相,质谱检测采用负离子选择反应监测模式。肝组织中汉黄芩素与汉黄芩素-7-O-葡萄糖醛酸苷在0.2-40μg/g范围内呈良好线性关系,方法学评价表明本法适用于动物静脉注射汉黄芩素后体内的组织分布研究。
出处 《Journal of Chinese Pharmaceutical Sciences》 CAS 2011年第3期282-289,共8页 中国药学(英文版)
基金 China National Key Hi-Tech Innovation Project for the R&D of Novel Drugs(Grant No.2009zx09102-032).
关键词 WOGONIN Wogonin-7-O-glucuronide Metabolite identification Liquid chromatography-tandem mass spectrometry 汉黄芩素 汉黄芩素-7-O-葡萄糖醛酸苷 代谢产物 液相色谱-质谱联用
  • 相关文献

参考文献15

  • 1Ye, F.; Wang, H.; Jiang, S.; Wu, J.; Shao, J.; Cheng, X. Tu, Y.; Zhang, D.Y. Nutr. Cancer. 2004, 49, 217-222.
  • 2Yu, J.; Liu, H.; Lei, J.; Tan, W.; Hu, X.; Zou, G. Phytother Res. 2007, 21,817-822.
  • 3Zhang, D.Y.; Wu, J.; Ye, F.; Xue, L.; Jiang, S.; Yi, J.; Zhang, W.; Wei, H.; Sung, M.; Wang, W.; Li, X. Cancer Res. 2003, 63, 4037-4043.
  • 4Zhang, H.W.; Yang, Y.; Zhang, K.; Qiang, L.; Yang, L.; Yang, L.; Hu, Y.; Wang, X.T.; You, Q.D.; Guo, Q.L. Eur. J. Pharmacol. 2008, 591, 7-12.
  • 5Lee, D.H.; Kim, C.; Zhang, L.; Lee, Y.J. Biochem. Pharmacol. 2008, 75, 2020-2033.
  • 6Li-Weber, M.; Cancer Treat. Rev. 2009, 35, 57-68.
  • 7Lu, N.; Gao, Y.; Ling, Y.; Chen, Y.; Yang, Y.; Gu, H.Y.; Qi, Q.; Liu, W.; Wang, X.T.; You, Q.D.; Guo, Q.L. Life Sci. 2008, 82, 956 963.
  • 8Lin, C.M.; Chang, H.; Chen, Y.H.; Li, S.Y.; Wu, 1.H.; Chiu, J.H. Int. Immunopharmacol. 2006, 6, 1690-1698.
  • 9Baumann, S.; Fas, S.C.; Giaisi, M.; Muller, W.W.; Merling, A.; Gulow, K.; Edler, L.; Krammer, EH.; Li- Weber, M. Blood. 2008, 111, 2354-2363.
  • 10Chung, H.; Jung, Y.M.; Shin, D.H.; Lee, J.Y.; Oh, M.Y.; Kim, H.J.; Jang, K.S.; Jeon, S.J.; Son, K.H.; Kong, G. Int. J. Cancer. 2008, 122, 816-822.

同被引文献2

引证文献1

二级引证文献3

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部